Alternative Multiple Sclerosis Therapy Navigation

|

Best products

Do you get dizzy or lightheaded? Then you
will want to check out Equitab

Are You Tired Of Sore Muscles?

The potent botanical ingredients in Myocil
work to help relax the muscle and to help repair
and rebuild damaged and strained tissue. You can
feel it start to work in as little as two days.
Myocil can work quickly to ease your pain,
discomfort, and swelling ..... Click Here For More

Are you sick of SPAM? Then Try this.
It is awesome! You can try for free and I know
you will love it!!
Click Here!

If you are looking for quality vitamin supplements then look no further.

USANA Essentials

 

Do you want to get your blog noticed?
Then try Blog Blaster.

Blog Blaster takes online Advertising to a new Level!
Submit your ad to 2 Million Blogs!

Best Alternative Multiple Sclerosis Therapy products

Cellscience Reviews Journal.
  Medical reviews Journal publishing articles from leading International authorities

No More MS. My Journey Back To Life
True Story of my recovery from Multiple Sclerosis.Near Death Experience.
Angel Encounters.
By Sue Ellen Dickenson

Newsletter

Main Alternative Multiple Sclerosis Therapy sponsors

Welcome to The Symptoms Of Multiple Sclerosis

	Enter your search terms
	Web www.thesymptomsofmultiplesclerosis.com Submit search form

Alternative Multiple Sclerosis Therapy Article

This is a selection among article about Alternative Multiple Sclerosis Therapy. For a permanent link to this article, or to bookmark it for further reading, click here.

With Reports Of Death, FDA Warns Multiple Sclerosis (MS) Patients Against Pharmaceutical Drug Tysabri

Greg Jones & Associates, a North Carolina-based law firm, in association with www.lawyersandsettlements.com, launches a marketing campaign to increase awareness of the Multiple Sclerosis drug, Tysabri. Makers of Tysabri, Biogen Idec Inc. and Elan Pharmaceuticals Inc., have recently taken the drug off the market and sent out warnings to doctors.

In November 2004, Biogen Idec and Elan Corporation received approval from the FDA to market and distribute Tysabri (natalizumab). Only four months later, February 2005, the drug was quickly removed from the market after the FDA received several reports of severe illness and death in patients prescribed Tysabri and Avonex. In several cases, the patient or corpse was diagnosed with Progressive Multifocal Leukoencephalopathy (PML), a rare brain infection that directly affects the central nervous system. Symptoms of PML are similar to a stroke: headaches, memory loss, speech and vision difficulties, limb weakness, and partial paralysis; the disease leads to coma then to death.

To date, approximately 3,000 patients have been involved in clinical trials or prescribed Tysabri for multiple sclerosis, Crohn's disease and rheumatoid arthritis. Biogen Idec and Elan Pharmaceuticals hope to redistribute the drug after extensive evaluations of Tysabri and the possible link to PML.

Biogen merged with IDEC Pharmaceuticals in 2003, creating the billion-dollar company, Biogen Idec, which is based in Cambridge, Massachusetts. Biogen Idec also has another MS drug in the news: the bread-winning drug, Avonex, the most widely prescribed Multiple Sclerosis drug in the world with revenues of $1.4 billion in 2004 has recently been linked to increased risk of liver damage and liver failure.

Greg Jones & Associates is urging patients that have had adverse side effects with the prescription drugs Tysabri or Avonex, to have their case reviewed at www.lawyersandsettlements.com; each case will be evaluated by a lawyer at no charge.

For more details about this product recall and potential class action lawsuit, visit https://www.lawyersandsettlements.com/case/tysabri

This article was posted on August 04, 2005

Alternative Multiple Sclerosis Therapy News

ASCEND Study to Evaluate the Effectiveness of TYSABRI® (natalizumab) as a Treatment for Secondary-Progressive Multiple ...

Biogen Idec and Elan Corporation, plc today announced a global Phase 3b study, ASCEND, that is being conducted to evaluate the effectiveness of TYSABRI as a treatment for secondary-progressive multiple sclerosis .

Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies

NEW YORK, Feb. 1, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Drug Delivery in Central Nervous System Diseases - technologies,markets ...

Personalized Medicine - Scientific & Commercial Aspects

NEW YORK, Feb. 1, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Personalized Medicine - scientific & commercial aspects http://www.reportlinker.com/p0203549/Personalized-Medicine---scientific--commercial-aspects.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=GenomicsThe ...

RNAi - Technologies, Markets and Companies

NEW YORK, Feb. 1, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: RNAi - technologies, markets and companies http://www.reportlinker.com/p0203551/RNAi---technologies-markets-and-companies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_TherapyRNA ...

FDA Updates TYSABRI® (natalizumab) Label to Include Anti-JC Virus Antibody Status as a PML Risk Factor

Today Biogen Idec and Elan Corporation, plc announced that the U.S. Food and Drug Administration has approved a product label change for TYSABRI that will help enable individual benefit risk assessment for patients with multiple sclerosis .